Scope and claims analysis plus US patent landscape for rotigotine stabilization solid dispersions (U.S. Patent 10,130,589)
Executive summary: U.S. Patent 10,130,589 is a claim-set centered on stabilizing rotigotine free base using solid dispersions of rotigotine free base in polyvinylpyrrolidone (PVP) at a narrow weight ratio of ~9:4 to ~9:6 (rotigotine:PVP), with dependent coverage narrowing to (i) non-crystalline rotigotine free base, (ii) poor solubility of rotigotine free base in the dispersing agent (<1 wt-%), (iii) use of amine-compatible silicone pressure sensitive adhesive(s) with defined rheology and adhesion metrics, (iv) containment in microreservoirs, and (v) downstream transdermal therapeutic systems and methods of preparing the systems. The estate’s practical enforcement footprint is strongest against competitors that make or sell a rotigotine patch incorporating a PVP-based solid dispersion at the specified ratio and structural/processing details consistent with the claims.
What does US Patent 10,130,589 claim for rotigotine stabilization using PVP solid dispersions?
Core claim nucleus (independent claim coverage). The patent’s primary scope is expressed through (a) a stabilization method and (b) solid dispersion compositions, both anchored to the same material definition:
Method for stabilizing rotigotine (Claim 1)
Claim 1 requires:
- Providing a solid dispersion comprising:
- polyvinylpyrrolidone, and
- a non-crystalline form of rotigotine free base
- Using a weight ratio of rotigotine free base : PVP in ~9:4 to ~9:6.
Enforcement implication: Accused products or processes that use amorphous/non-crystalline rotigotine free base stabilized in PVP at that ratio fit the claim’s material definition even if the final dosage form differs, but later claims (8–10, 11) push coverage into patch architectures.
Solid dispersion definition (Claim 2)
Claim 2 expands from “stabilizing method” to composition form:
- A solid dispersion comprising:
- a dispersing agent, and
- a dispersed phase
- where the dispersed phase contains:
- rotigotine free base + PVP
- with the same ~9:4 to ~9:6 weight ratio.
Enforcement implication: Claim 2 covers dispersing-agent-containing solid dispersions where the rotigotine/PVP portion sits as a defined dispersed phase. This is a typical pivot point for design-around attempts: omit PVP, move away from the ratio window, or change rotigotine’s form (salt vs free base; crystalline vs amorphous).
How narrow is the rotigotine:PVP ratio window and why does it matter for claim scope?
The claims repeatedly lock the composition to rotigotine free base to PVP between:
What that does legally: the claim is a numerical range for a defined weight ratio. In practice, the claim scope is strongest for formulations that match the ratio within typical manufacturing tolerances, and weaker where a competitor shifts ratio outside the endpoints.
Where the ratio appears across the claim set:
- Claim 1 (stabilizing method)
- Claim 2 (solid dispersion)
- Claim 7 (pharmaceutical composition)
- Claim 8 (transdermal therapeutic system with silicone PSA + specified loading)
- Claim 9 (microreservoir structure)
- Claim 10 (transdermal system comprising the solid dispersion)
- Claim 11 (method of preparing the system)
This repetition makes the ratio window a central claim feature. Any landscape analysis for freedom-to-operate (FTO) must treat this ratio as the most likely “hard stop” lever for generics and reformulation teams.
Does US Patent 10,130,589 require “non-crystalline rotigotine free base” or “poor solubility” in the dispersing agent?
Non-crystalline requirement appears in Claim 1.
- Claim 1 explicitly requires a non-crystalline form of rotigotine free base inside the solid dispersion.
Poor-solubility limitation appears in Claim 3.
- Claim 3 requires that solubility of rotigotine free base in the dispersing agent is below 1 wt-%.
Why this matters:
- Claim 1 is already narrower than a generic “PVP stabilized” story because it calls out non-crystalline rotigotine free base.
- Claim 2 does not, on its face, restate “non-crystalline” or the “<1 wt-%” limitation; it can still be asserted if the accused dispersion necessarily satisfies those properties, but the cleanest match is:
- non-crystalline rotigotine free base in PVP at the ratio, plus
- dispersing agent that dissolves rotigotine free base poorly.
Landscape consequence: Competitors that preserve rotigotine’s physicochemical form as crystalline or use a dispersing system where rotigotine has higher solubility have better arguments against the narrower dependents.
Which dispersing agents are protected: silicone pressure sensitive adhesives and performance thresholds?
The patent’s dependent claims define the dispersing agent architecture around amine-compatible silicone pressure sensitive adhesive(s) and set measurable constraints.
Silicone PSA is expressly required (Claim 4)
- Claim 4 requires the dispersing agent comprise at least one silicone pressure sensitive adhesive.
Two-silicone mixture and complex viscosity (Claim 5)
- Claim 5 requires:
- mixture of a first and second silicone PSA, and
- the solid dispersion has a complex viscosity between 5 and 15 MP.
Viscosity windows expanded in preparation claims (Claims 13–16, 19–22)
Several dependent claim layers specify adhesive complex viscosities, including:
- Claim 13: first adhesive complex viscosity between 40 and 250 MP
- Claim 14: second adhesive complex viscosity between 1 and 10 MP
- Claim 15: overall dispersing agent complex viscosity between 5 and 25 MP
- Claim 16: dispersing agent adhesives with overall solid dispersion complex viscosity between 5 and 15 MP
- Claim 19–22 mirror Claim 13–16 style limitations but applied to the solid dispersion definition.
Key enforcement point: Claim scope tightens when the dispersing system includes silicone PSAs with defined rheology. Patch manufacturers that use different adhesive chemistries (non-silicone PSA) or fail the complex-viscosity window create a clearer non-infringement pathway for dependents 4–6 and 13–23.
What microreservoir architecture is required, and how does it affect design-around options?
The patent ties the formulation to a structural deployment in a transdermal patch:
- Claim 6: dispersed in a multitude of microreservoirs
- Claim 9: rotigotine free base + PVP in a multitude of microreservoirs
- Claim 10: transdermal therapeutic system comprising the solid dispersion of Claim 2
- Claim 8 also covers transdermal system including the specified adhesive and loading, with microreservoir support.
Design-around angle: A competitor could potentially argue non-infringement by using a different reservoir architecture (for example, matrix dispersion rather than microreservoirs) while still using a PVP solid dispersion, but the independent claim coverage may still attach via other dependents depending on how the product is built and characterized.
What transdermal therapeutic system loading and adhesive features are claimed?
Transdermal therapeutic system with amine-compatible silicone PSA (Claim 8)
Claim 8 requires:
- a transdermal therapeutic system comprising:
- at least one amine-compatible silicone pressure sensitive adhesive
- about 0.1 to about 3.15 mg/cm² rotigotine free base
- polyvinylpyrrolidone
- with rotigotine:PVP ~9:4 to ~9:6.
Loading window is another hard constraint. Dependents can become the primary infringement battleground for competitors whose patches use substantially different mg/cm² dosing.
Transdermal system with solid dispersion (Claim 10)
- Covers a transdermal therapeutic system comprising a solid dispersion according to Claim 2.
This creates a pathway to assert Claim 10 even if the competitor does not replicate every dependent adhesive-performance limitation, as long as the sold product includes the claimed solid dispersion composition (Claim 2).
How do adhesion and shear performance metrics narrow the dispersing agent scope?
The patent adds quantitative testable adhesion constraints, which matter for claim construction and infringement proof.
Peel adhesion constraints (Claim 17 and Claim 23)
Static shear adhesion constraints (Claim 18 and Claim 24)
Practical enforcement impact: these metrics can be powerful in patch technology litigation because they map to standardized testing. Competitors can attempt to:
- change the silicone formulation,
- adjust viscosity rheology,
- or target adhesion performance outside the defined windows.
However, infringement defenses may still face hurdles if the competitor can’t isolate the accused composition from the performance characteristics used during testing.
What is the likely effective “scope footprint” across method, composition, and product claims?
A simplified claim-to-coverage map:
| Claim cluster |
What is required |
What competitors must match |
| Stabilization method (Claim 1) |
solid dispersion with PVP + non-crystalline rotigotine free base at ratio |
non-crystalline rotigotine free base stabilized in PVP at ~9:4 to ~9:6 |
| Solid dispersion composition (Claim 2) |
dispersing agent + dispersed phase of rotigotine free base + PVP at ratio |
inclusion of PVP solid dispersion at ratio in the dispersion system |
| Solubility + silicone (Claims 3–4) |
rotigotine solubility in dispersing agent <1 wt-%; silicone PSA |
low solubility dispersing system + silicone PSA |
| Silicone rheology (Claims 5, 13–16, 19–22) |
complex viscosity windows for adhesives/solid dispersion |
rheology match for two adhesive components and overall |
| Microreservoir structure (Claims 6, 9) |
multiple microreservoirs |
patch architecture with microreservoir distribution |
| Transdermal dosing (Claim 8) |
silicone PSA + amine-compatible, loading 0.1–3.15 mg/cm², PVP at ratio |
matching mg/cm² and adhesive + PVP ratio |
| Adhesion metrics (Claims 17, 18, 23, 24) |
peel and static shear within windows |
match adhesion properties and thickness parameters |
How does this patent likely position relative to rotigotine patch IP around free base stabilization and transdermal systems?
Claim strategy pattern: This estate is drafted to capture:
- the stabilized intermediate (solid dispersion), and
- the final delivery (transdermal therapeutic system),
with additional dependent constraints for the adhesive and microreservoir embodiment.
Competitive landscape implication (technology levers):
- Material lever: change rotigotine form (salt vs free base; crystalline vs amorphous/non-crystalline) to exit Claim 1 and potentially Claim 3.
- Composition lever: shift ratio outside ~9:4 to ~9:6.
- Polymer lever: eliminate or substitute PVP.
- Adhesive lever: remove silicone PSA or change to a silicone PSA chemistry not meeting complex viscosity and adhesion metrics.
- Architecture lever: avoid “multitude of microreservoirs” (matrix/other architecture).
Each lever correlates to a specific dependent claim group that narrows infringement exposure.
What related patents are likely in the same technological family and adjacent claim space?
Coverage adjacency (not enumerating specific numbers). Without the complete specification and bibliographic record, the most credible neighboring patent categories around this claim set are:
- rotigotine solid dispersions with polymers such as PVP (and sometimes other K-value or molecular weight variants),
- stabilization of rotigotine free base in amorphous or non-crystalline form,
- transdermal patch architectures using microreservoirs,
- silicone PSA systems designed for amine compatibility and controlled adhesive rheology,
- combination patents linking stabilized API to patch manufacturing parameters and performance testing.
This patent’s specific claim language (ratio range; non-crystalline; silicone PSA complex viscosity and peel/shear) indicates it is one of the more targeted “bridge” patents between API stabilization and final patch engineering.
Key design-around scenarios for a generic or reformulation program targeting rotigotine patches
Given the claim language, the highest-probability non-infringement or settlement leverage points are:
- Exit the ratio window: produce rotigotine:PVP outside ~9:4 to ~9:6.
- Avoid PVP solid dispersion: replace PVP with another polymer or different solid-state system.
- Change rotigotine physical form: use crystalline rotigotine or a free-base form that does not meet “non-crystalline” in the stabilization context.
- Remove silicone PSA (for dependents): use a non-silicone PSA system, or a silicone PSA that does not meet viscosity/adhesion windows.
- Alter microreservoir architecture: move to a different patch structure that does not use microreservoirs.
- Shift dosing/loading: for Claim 8, alter mg/cm² outside 0.1–3.15.
These are also the strongest grounds for invalidity or non-infringement narratives, because each maps to a distinct claim element rather than a broad, generalized “different process” argument.
What matters most for litigation: which claims are most assertable and most attackable?
Most assertable (typical):
- Claim 2 and Claim 10 because they tie to composition and product inclusion of the claimed solid dispersion.
- Claim 8 if the accused patch dosing and adhesive type align.
Most attackable (typical):
- Dependent claims 3–6 and 13–24 because they rely on measurable constraints (solubility, microreservoir presence, complex viscosity, peel and shear), which can be operationally tested and engineered around.
Most fact-sensitive:
- “Non-crystalline” characterization (Claim 1).
- Whether the patch truly uses “microreservoirs” (Claims 6 and 9).
- Silicone PSA rheology and adhesion metrics (Claims 5, 13–18, 23–24).
Key Takeaways
- U.S. Patent 10,130,589 is anchored to PVP-based solid dispersions stabilizing rotigotine free base using a tight weight ratio ~9:4 to ~9:6.
- The claims progressively narrow to a specific embodiment: non-crystalline rotigotine free base, silicone pressure sensitive adhesives that are amine-compatible, and performance-constrained adhesives defined by complex viscosity, peel adhesion, and static shear adhesion.
- The product coverage is aimed at transdermal therapeutic systems with microreservoir architecture and a rotigotine loading window of ~0.1 to ~3.15 mg/cm² (Claim 8).
- For competitive programs, the most direct design-around levers are ratio, PVP elimination/substitution, rotigotine physical form, silicone PSA/rheology/adhesion criteria, and microreservoir vs alternative patch architecture.
FAQs
1) Does US 10,130,589 protect rotigotine patches that use rotigotine salt instead of rotigotine free base?
The claims are drafted around rotigotine free base specifically, including a “non-crystalline form” limitation in Claim 1. Rotigotine salt systems can be outside the literal claim scope depending on how “free base” is defined and generated in situ.
2) Can a competitor avoid infringement by changing adhesive type but keeping the same PVP solid dispersion ratio?
Changing dispersing agent type can avoid dependence on the silicone PSA-specific limitations (Claims 4–6, 13–18, 19–24). However, coverage under Claim 2/10 depends on whether the dispersing agent is still part of the claimed solid dispersion system.
3) What is the most critical parameter to measure for enforcement: ratio or adhesion metrics?
The ratio is the repeated independent/central element across the claim set. Adhesion and rheology metrics mainly affect dependent claim layers, but they become critical where the accused product matches the silicone-PSA embodiment.
4) How does “microreservoirs” change the infringement risk compared with a matrix patch?
Claims 6 and 9 require microreservoir architecture. A matrix patch can reduce risk against those dependent claims, though Claim 2/10 may still be asserted if the solid dispersion composition matches.
5) Is this patent limited to a specific rotigotine dose per patch area?
Only Claim 8 includes a defined loading window (0.1 to 3.15 mg/cm²). Other claims can cover solid dispersion and system structures without locking to that dosing range.
References (APA)
No external sources were cited in this analysis.
